Australia's Neuren Pharmaceuticals hits more than 1-year high on strong HY results
27/08/2025 04:38
** Neuren Pharmaceuticals NEU.AX rises as much as 6.3% to A$18.92, highest since August 2, 2024 ** Drug developer reports HY profit attributable of A$15 mln ($9.8 mln), higher than year-ago A$8 mln ** HY revenue from ordinary activities rises 24% ** YTD, NEU gains 50.6% ($1 = A$1.5389) (Reporting by Ananya Verma in Bengaluru) ((ananya.verma@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union